| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Modified Organism
Record information and status
Record ID
Date of creation
2019-06-21 13:31 UTC (austein.mcloughlin@cbd.int)
Date of publication
2019-06-21 13:31 UTC (austein.mcloughlin@cbd.int)

Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.

LMO name
Transformation event
Dr Marielle Van Hulten
Director of Biology Discovery
EU Geohead Poultry
MSD Animal Health
Intervet International BV
Wim de Korverstraat 35
Boxmeer the Netherlands
Innovax® ILT is a live recombinant vaccine containing Herpesvirus Turkey (HVT) strain FC-126 expressing glycoproteins D and I (gD and gI) from Infectious Laryngotracheitis virus (ILT) strain USDA Challenge Lot No. 83-2. HVT virus induces immunity against Marek's Disease (MD), and gD and gI from ILT virus induce immunity against ILT virus. Thus, the recombinant viral vaccine Innovax® ILT gives protection against both Marek's and ILT disease.
Recipient Organism or Parental Organisms
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Meleagrid alphaherpesvirus 1 - Turkey herpesvirus, Meleagrid herpesvirus 1
Point of collection or acquisition of the recipient organism
Meleagrid herpesvirus 1 strain FC-126
Characteristics of the transformation process
Techniques used for the modification
  • Recombination
Introduced or modified genetic elements
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
Glycoprotein D - Gallid alphaherpesvirus 1 - ILTV
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Glycoprotein I - Gallid alphaherpesvirus 1 - ILTV
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Notes regarding the genetic elements introduced or modified in this LMO
Information regarding the genetic construction the recombinant virus has not been provided.
LMO characteristics
Modified traits
Common use(s)
  • Vaccine

Records referencing this document (2)
2record(s) found
Country's Decision or any other Communication1 record
Risk Assessment1 record